Randomized Phase II Study of Whole-Brain Radiation Therapy

with or without Concomitant Temozolomide for Brain Metastases from Breast Cancer

K. I. CAO1, N. LEBAS1, S. GERBER1, C. LEVY2, A. FOURQUET1, F. CAMPANA1, R. LE SCODAN3, B. DE LA LANDE4, C. BOURGIER5, J.-Y. PIERGA1, A. GOBILLION1, A. SAVIGNONI1, Y. M KIROVA1

1INSTITUT CURIE, PARIS, FRANCE ²CENTRE FRANÇOIS BACLESSE, CAEN, FRANCE 3CENTRE HOSPITALIER PRIVÉ SAINT-GRÉGOIRE, SAINT-GRÉGOIRE, FRANCE 4INSTITUT CURIE, SAINT-CLOUD, FRANCE 5INSTITUT GUSTAVE ROUSSY, VILLEJUIF, FRANCE

NO DISCLOSURE

Main Results

Primary end-point: ORR WBRT + TMZ: 30% (n = 15)

WBRT: 36% (n = 18)

No complete response

Survival Median OS: 9.4 m WBRT + TMZ / 11.1 m WBRT

2 years – OS: 18 % (each arm)

Median PFS: 6.8 m WBRT + TMZ / 7.4 m WBRT

Discussion

Strenghts

Prospective randomized study with long-term follow-up

Homogeneous study population (only primary breast cancer)

Weaknesses

No QOL assessment No molecular stratification No MGMT status

Take home messages

WBRT combined with temozolomide did not improve brain control among patients with brain metastases from breast cancer.

WBRT remains a standard treatment in this population. WBRT + TMZ in TNBC ?

THANK YOU.